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Introduction {#jah32175-sec-0004}
============

Patients with underlying heart disease and diabetes mellitus have metabolic disturbances including hyperinsulinemia and insulin resistance that can influence heart failure incidence and progression.[1](#jah32175-bib-0001){ref-type="ref"}, [2](#jah32175-bib-0002){ref-type="ref"}, [3](#jah32175-bib-0003){ref-type="ref"} It has been hypothesized that medications that improve insulin sensitivity and limit the potential for weight gain, such as metformin, could prevent heart failure,[1](#jah32175-bib-0001){ref-type="ref"}, [4](#jah32175-bib-0004){ref-type="ref"} whereas medications that increase endogenous hyperinsulinemia[5](#jah32175-bib-0005){ref-type="ref"} and facilitate weight gain may increase heart failure risk.[1](#jah32175-bib-0001){ref-type="ref"}, [6](#jah32175-bib-0006){ref-type="ref"}, [7](#jah32175-bib-0007){ref-type="ref"}, [8](#jah32175-bib-0008){ref-type="ref"}

The theory that insulin sensitization may also improve cardiovascular outcomes compared to insulin provision prompted the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.[9](#jah32175-bib-0009){ref-type="ref"} That trial used a factorial design to randomize patients with diabetes mellitus and cardiovascular disease to either early revascularization or intensive medical therapy. Medical therapy was further randomized as insulin sensitization (metformin and/or a thiazolidinedione) or insulin provision (sulfonylurea and/or insulin). Heart failure was considered an adverse outcome and occurred in 22.6% of those randomized to insulin sensitization compared with 20.0% of those randomized to insulin provision (*P*=0.13). The effects of metformin and thiazolidinedione could not be separated, and by 3 years 75% of patients in the insulin‐sensitizing group were taking thiazolidinedione and more than 25% had also added insulin and/or a sulfonylurea. Although randomized trials are ideal for assessing efficacy, they often lack the ability to assess whether treatments work under real‐world conditions with a broader set of participants.[10](#jah32175-bib-0010){ref-type="ref"}

A recent statement by the American Heart Association reported that metformin remains concerning for patients with established heart failure (level C evidence) because of the risk of lactic acidosis that was described with its predecessor, phenformin. Sulfonylureas were not considered in their report of drugs associated with heart failure, which focused on more frequently described associations including thiazolidinediones and saxagliptin.[11](#jah32175-bib-0011){ref-type="ref"} It remains uncertain if common initial diabetes mellitus medications such as sulfonylurea differ from metformin on heart failure outcomes because heart failure has been an infrequent primary outcome in clinical trials.[12](#jah32175-bib-0012){ref-type="ref"} Our aim was to test the hypothesis that heart failure outcomes would be higher among patients initiating sulfonylurea for diabetes mellitus treatment compared to metformin because of the potential for more weight gain.

Methods {#jah32175-sec-0005}
=======

Study Design and Data Sources {#jah32175-sec-0006}
-----------------------------

We assembled a retrospective cohort of Veterans Health Administration (VHA) patients.[13](#jah32175-bib-0013){ref-type="ref"} Pharmacy data included dispensed prescriptions, date filled, days supplied, and number of pills. Demographic, diagnostic, and procedure information identified inpatient and outpatient encounters. We collected laboratory results and vital signs data from clinical sources. For Medicare or Medicaid enrollees, we obtained enrollment, claims files, and prescription (Part D) data.[14](#jah32175-bib-0014){ref-type="ref"}, [15](#jah32175-bib-0015){ref-type="ref"}, [16](#jah32175-bib-0016){ref-type="ref"}, [17](#jah32175-bib-0017){ref-type="ref"} We obtained dates and cause of death from vital status and the National Death Index files.[18](#jah32175-bib-0018){ref-type="ref"} The institutional review board of Tennessee Valley Healthcare System approved this study with a waiver of informed consent.

Study Population {#jah32175-sec-0007}
----------------

The population was made up of veterans aged ≥18 years who received regular VHA care at least once every 365 days for 2 or more years. New users of oral hypoglycemics were identified as patients who filled a first hypoglycemic prescription from October 2001 through December 2011 with ≥730 days of baseline data available and without any diabetic drug fill in the 180 days prior to that first fill (Figure [S1](#jah32175-sup-0001){ref-type="supplementary-material"}). The date of first new use was termed the index date. We selected those who were adherent by including patients who refilled their incident medication at least once in the 180 days after the index date. This prevented the inclusion of those with early nonadherence and those who switched to alternate regimens. We excluded patients receiving hospice care. We also excluded patients with evidence of chronic kidney disease including females with creatinine \>1.4 mg/dL and males with a creatinine \>1.5 mg/dL on the index date because during this time in the United States metformin was not recommended for these patients.[19](#jah32175-bib-0019){ref-type="ref"}

Exposures {#jah32175-sec-0008}
---------

The exposures were metformin and a sulfonylurea (glyburide, glipizide, or glimepiride). Follow‐up began at 180 days after the incident prescription and continued through an outcome (described below) or censoring event. Patients were censored on the 181st day without medical contact (inpatient, outpatient, or pharmacy use) or nonpersistence, defined as the 91st day without the hypoglycemic therapy or addition of a second hypoglycemic drug, reaching the previously described creatinine threshold, death, or study end (December 31, 2011). Seventy percent of our population received 90‐day prescriptions, and 93% and 94% of metformin and sulfonylurea users, respectively, refilled their prescriptions within 90 days.[20](#jah32175-bib-0020){ref-type="ref"}

Outcome {#jah32175-sec-0009}
-------

The primary outcome was a composite of either hospitalization for a diagnosis of heart failure or cardiovascular death. The secondary outcomes evaluated each component separately, and the composite primary outcome also included emergency department visits for heart failure that did not result in hospitalization.

We defined heart failure hospitalization by adapting the validated definitions used in the Mini‐Sentinel to identify heart failure outcomes.[21](#jah32175-bib-0021){ref-type="ref"} Events were defined as a primary discharge diagnosis of heart failure (ICD9‐CM: 425.X; 428.X; 404.01, 404.03, 404.11, 404.13, 398.91, 402.01, 402.11, 402.91, 404.91, 404.93) or a diagnosis‐related group (DRG) code for heart failure (DRG 127 before fiscal year 2008; and 291‐293 after fiscal year 2008). Cardiovascular deaths were identified based on death certificates with an ICD‐10 coded underlying cause of death including I00‐I78 (cardiovascular deaths) or R98, R99, R960, R961 (unattended deaths), excluding I30.X (diseases of the pericardium). This definition was derived from the Centers for Disease Control and Prevention and validated strategies for identification of sudden cardiac deaths.[22](#jah32175-bib-0022){ref-type="ref"}

Emergency department visits for heart failure were included if there was a coded visit (CPT code 99281, 99282, 99283, 99284, 99285) and a primary heart failure diagnosis (listed above) on the same day. Any emergency department visit that resulted in hospitalization within a 48‐hour time frame was considered a single hospitalization event.

Covariates {#jah32175-sec-0010}
----------

Study covariates were measured during the 730 days before the index date and included age, sex, race (white, black, other), fiscal year, healthcare utilization (hospitalization, nursing home, number of outpatient visits or medications, Medicare or Medicaid use in past year), and physiologic variables (body mass index \[BMI\], blood pressure, hemoglobin \[Hb\]A~1c~, low‐density lipoprotein levels, presence of proteinuria, and creatinine), which were used to calculate estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation,[23](#jah32175-bib-0023){ref-type="ref"} selected medications, smoking, and comorbidities (Table [S1](#jah32175-sup-0001){ref-type="supplementary-material"}). Missing covariates were handled with multiple imputations using predictive mean matching with bootstrapping.[24](#jah32175-bib-0024){ref-type="ref"} All covariates from the primary analysis as well as an indicator for each Veterans Integrated Service Networks were included in 20 imputation models to compute final estimates.

Statistical Analyses {#jah32175-sec-0011}
--------------------

The primary analysis compared the hazard of heart failure hospitalization or cardiovascular death between exposure groups in a propensity score--matched cohort. The propensity score modeled the probability of sulfonylurea given covariates and VHA medical center. The 1:1 matching was performed on the log odds of the propensity scores using an 8:1 digit matching algorithm (Table [S2](#jah32175-sup-0001){ref-type="supplementary-material"}, Figure [S2](#jah32175-sup-0001){ref-type="supplementary-material"}).[25](#jah32175-bib-0025){ref-type="ref"}, [26](#jah32175-bib-0026){ref-type="ref"} Cox proportional hazards models were used to compare outcomes for sulfonylurea versus metformin (referent) in the matched cohort adjusted for covariates. The proportional hazards assumptions were verified through examination of log‐log plots.

Evaluation of a Positive Control: Sensitivity and Subgroup Analyses {#jah32175-sec-0012}
-------------------------------------------------------------------

We conducted planned sensitivity analyses. First, we used the initial regimen that defined exposure and ignored subsequent regimen changes or the 90‐day refill requirement (persistent exposure not required). This analysis is akin to intention‐to‐treat analysis in clinical trials; however, although it increases follow‐up time and events, it allows for exposure time misclassification due to patient non‐adherence. Second, because the main analysis included a matched subset of the population, we conducted an inverse probability of treatment weighted analysis to include all patients. For these analyses, we used the previously described propensity score and weighted the sulfonylurea users to resemble the metformin population and approximate a balanced cohort. For this analysis we also included new users of thiazolidinedione (a small, select group[27](#jah32175-bib-0027){ref-type="ref"}) as a positive control group because of the well‐described association of thiazolidinediones with heart failure outcomes.[28](#jah32175-bib-0028){ref-type="ref"}, [29](#jah32175-bib-0029){ref-type="ref"} Third, in the cohort construction we were interested in long‐term outcomes; therefore, follow‐up began 180 days post--treatment initiation to minimize the inclusion of those with early nonadherence and regimen switching. To evaluate early outcome differences between groups, we performed an alternate weighted analysis with a new‐user design in which follow‐up began at the index date and continued through the first 180 days.[30](#jah32175-bib-0030){ref-type="ref"}, [31](#jah32175-bib-0031){ref-type="ref"} For this analysis we also included thiazolidinedione users. We conducted subgroup analyses, stratifying by history of heart failure diagnosis (yes, no), age (≥65, \<65 years), and race (black, white). Finally, we explored the sensitivity of our main analysis to potential unmeasured confounding.[32](#jah32175-bib-0032){ref-type="ref"} For this we assessed the strength of the association of an unmeasured binary confounder and its hypothetical distribution between exposure groups that would be required to explain our findings. Analyses were conducted using R (<http://www.r-project.org>) and SAS for Windows 9.2. (SAS Institute Cary, North Carolina).

Results {#jah32175-sec-0013}
=======

Study Cohort and Patient Characteristics {#jah32175-sec-0014}
----------------------------------------

There were 407 145 patients who started an antidiabetic medication (no hypoglycemics filled in the previous 180 days). Of these, 102 457 initiated regimens other than metformin or a sulfonylurea; 142 were excluded for data errors; 21 474 were excluded for elevated creatinine or hospice care; 23 207 died or were censored during the 6‐month lag time, and 53 806 were not persistent on their initial regimen at the start of follow‐up (early stoppers N=33 363; early intensifiers N=20 443). Thus, there were 126 867 metformin initiators and 79 192 sulfonylurea initiators (46.2% glipizide, 53.1% glyburide, and 0.7% glimepiride; Figure [1](#jah32175-fig-0001){ref-type="fig"}). After 1:1 propensity score matching, our study included 65 986 patients in each group, and baseline characteristics were similar (Table [1](#jah32175-tbl-0001){ref-type="table-wrap"}, Figure [S3](#jah32175-sup-0001){ref-type="supplementary-material"}). Characteristics of patients excluded from the PS match are shown in Table [S3](#jah32175-sup-0001){ref-type="supplementary-material"} Characteristics of patients included in the weighted analysis (including 6945 thiazolidinedione new users as a positive control group) are listed in Table [S4](#jah32175-sup-0001){ref-type="supplementary-material"}

![Flow of eligible patients included.](JAH3-6-e005379-g001){#jah32175-fig-0001}

###### 

Characteristics of Patients in the Unmatched and Matched Cohorts

  Characteristics                                                                                  Full Cohort         Propensity‐Matched Cohort                                           
  ------------------------------------------------------------------------------------------------ ------------------- --------------------------- ------------------- ------------------- -------
  Age, median (IQR)                                                                                68 (58, 77)         62 (56, 72)                 66 (57, 75)         66 (58, 75)         0.013
  Male, %                                                                                          97                  95                          97                  97                  0.006
  Race, %                                                                                                                                                                                  
  White                                                                                            77                  76                          77                  77                  0.002
  Black                                                                                            14                  13                          13                  14                  0.003
  Hispanic/other                                                                                   5                   4                           5                   5                   0.004
  Missing                                                                                          4                   7                           5                   4                   0.008
  HbA~1c~, % median (IQR)                                                                          6.9 (6.3, 7.8)      6.8 (6.3, 7.5)              6.9 (6.3, 7.7)      6.9 (6.3, 7.6)      0.024
  Missing measurement, %                                                                           22                  19                          21                  21                  0
  Low‐density lipoprotein, mg/dL, median (IQR)                                                     98 (77, 122)        99 (79, 123)                98 (78, 123)        98 (78, 122)        0.007
  Missing measurement, %                                                                           31                  25                          29                  29                  0.002
  Creatinine mg/dL, median (IQR)                                                                   1.1 (0.9, 1.2)      1.0 (0.9, 1.1)              1.0 (0.9, 1.2)      1.0 (0.9, 1.2)      0.029
  Glomerular filtration rate mL/min, median (IQR)                                                  77 (64, 94)         84 (71, 99)                 80 (67, 97)         79 (67, 96)         0.019
  Missing measurement, %                                                                           18                  14                          17                  17                  0
  Proteinuria, (%) negative                                                                        47                  51                          48                  48                  0.001
  Urine protein trace or 1+                                                                        11                  10                          11                  11                  0.001
  Proteinuria present at 2+                                                                        2                   1                           2                   2                   0
  Proteinuria present at 3+                                                                        0.41                0.27                        0                   0                   0
  Proteinuria present at 4+                                                                        0.05                0.02                        0                   0                   0
  Missing measurement, %                                                                           40                  39                          40                  39                  0.002
  Systolic blood pressure, mm Hg, median (IQR)                                                     136 (124, 148)      135 (124, 146)              136 (124, 148)      136 (124, 148)      0.001
  Diastolic blood pressure, mm Hg, median (IQR)                                                    76 (68, 83)         77 (70, 84)                 76 (68, 84)         76 (68, 84)         0.006
  Missing measurement, %                                                                           2.6                 1.9                         2                   2                   0.001
  Body mass index, kg/m^2^, median (IQR)                                                           30.2 (26.9, 34.1)   31.8 (28.4, 36.0)           30.7 (27.4, 34.6)   30.7 (27.4, 34.6)   0.003
  Missing measurement, %                                                                           4.3                 2.9                         4                   4                   0.002
  Baseline comorbidities, %[b](#jah32175-note-0004){ref-type="fn"}                                                                                                                         
  Malignancy                                                                                       7                   5                           6                   6                   0.002
  Liver/respiratory failure                                                                        2                   1                           1                   1                   0.005
  HIV                                                                                              0.6                 0.4                         1                   0                   0.004
  Congestive heart failure                                                                         10                  4                           6                   6                   0.003
  Cardiovascular disease                                                                           28                  22                          27                  27                  0.001
  Serious mental illness                                                                           16                  17                          17                  17                  0
  Smoking                                                                                          11                  12                          11                  11                  0.001
  Chronic obstructive pulmonary disease                                                            15                  12                          13                  13                  0
  Cardiac valve disease                                                                            2                   1                           2                   2                   0.001
  Arrhythmia                                                                                       11                  7                           9                   9                   0.002
  Parkinson                                                                                        0.8                 0.5                         1                   1                   0.002
  Use of medications, %                                                                                                                                                                    
  Angiotensin‐converting enzyme inhibitors                                                         53                  53                          53                  53                  0.003
  Angiotensin II receptor blockers                                                                 7                   8                           7                   7                   0.003
  β‐Blockers                                                                                       44                  40                          42                  42                  0.005
  Calcium channel blockers                                                                         26                  24                          26                  26                  0.002
  Thiazide and potassium‐sparing diuretics                                                         31                  33                          31                  31                  0.006
  Nonselective α blockers                                                                          16                  14                          15                  16                  0.009
  Loop diuretics                                                                                   18                  10                          14                  14                  0.003
  Other antihypertensive medications                                                               26                  24                          25                  25                  0.002
  Statin lipid‐lowering drugs                                                                      58                  64                          60                  60                  0.002
  Nonstatin lipid‐lowering drugs                                                                   15                  18                          16                  16                  0.001
  Antiarrhythmics, digoxin, and inotropes                                                          2                   2                           2                   2                   0.005
  Anticoagulants, platelet inhibitors                                                              8                   5                           7                   7                   0.001
  Nitrates                                                                                         15                  11                          14                  14                  0.004
  Aspirin                                                                                          18                  17                          18                  18                  0
  Antipsychotics                                                                                   7                   8                           8                   8                   0.002
  Oral glucocorticoids                                                                             12                  11                          12                  12                  0.001
  Indicators of health care utilization, %                                                                                                                                                 
  Hospitalized in last year (Veterans Health)                                                      9                   6                           8                   8                   0.007
  Hospitalized in last year (Medicare/Medicaid)                                                    11                  6                           8                   8                   0
  Hospitalized within 30 days (Veterans Health)                                                    4                   3                           3                   3                   0.003
  Hospitalized within 30 days (Medicare/Medicaid)                                                  3                   1                           2                   2                   0.004
  Days from prior heart failure hospitalization to incident diabetes mellitus drug, median (IQR)   218 (65, 427)       266 (97, 456)               268 (81, 476)       257 (95, 440)       0.032
  Nursing home encounter in last year                                                              0.07                0.05                        0                   0                   0.001
  Number medications                                                                               10 (7, 14)          9 (6, 14)                   10 (6, 14)          10 (6, 14)          0.003
  Outpatient visits in past year                                                                   5 (3, 9)            5 (3, 9)                    5 (3, 9)            5 (3, 9)\]          0.003
  Medicare use in last year                                                                        34                  26                          32                  32                  0.002
  Medicaid use in last year                                                                        15                  9                           12                  12                  0.001

IQR indicates interquartile range.

Standardized mean differences are the absolute difference in means or percentage divided by an evenly weighted pooled standard deviation, or the difference between groups in number of standard deviations. In the matched cohort all standardized differences were not statistically significant (see Figure [S3](#jah32175-sup-0001){ref-type="supplementary-material"} for the plot of the mean standardized differences of the prematched and matched cohort).

Definitions of comorbidities included in Table [S1](#jah32175-sup-0001){ref-type="supplementary-material"}.

John Wiley & Sons, Ltd

In the primary analysis, the median (interquartile range \[IQR\]) follow‐up prior to censoring or reaching an outcome was 1.1 (0.4, 2.7) years among metformin users and 0.9 (0.4, 2.1) year among sulfonylurea users. Reasons for censoring were nonpersistence (49% metformin versus 46% sulfonylurea); additional therapy (24% versus 28%); no healthcare contact (5% versus 5%); reaching creatinine threshold (10% versus 11%); study end (9% versus 5%); or death (2% versus 2%). In the sensitivity analysis in which regimen persistence was not required, the median follow‐up time was 5.1 (3.6, 6.6) versus 5.0 (3.0, 6.5) years among metformin and sulfonylurea users, respectively.

Time to Heart Failure Events or Cardiovascular Death {#jah32175-sec-0015}
----------------------------------------------------

There were 1236 events (1184 heart failure hospitalizations and 52 cardiovascular deaths) among sulfonylurea initiators and 1078 events (1043 heart failure hospitalizations and 35 cardiovascular deaths) among metformin initiators, yielding 12.4 versus 8.9 events per 1000 person‐years of use, respectively (adjusted hazard ratio \[aHR\] 1.32, 95%CI \[1.21, 1.43\]) (Table [2](#jah32175-tbl-0002){ref-type="table-wrap"}, Figure [2](#jah32175-fig-0002){ref-type="fig"}). Event rates for heart failure hospitalization alone comprised the majority of the outcomes and were 11.9 and 8.6 per 1000 person‐years among sulfonylurea and metformin users (aHR 1.30 \[1.20, 1.42\]). Event rates for cardiovascular death alone were 5.2 and 2.9 per 10 000 person years among sulfonylurea and metformin users (aHR 1.76 \[1.14, 2.71\]). The secondary outcome that added emergency room visits yielded event rates of 15.1 versus 11.0 per 1000 person‐years among sulfonylurea and metformin users (aHR 1.30 \[1.20, 1.40\]).

###### 

Rates and Adjusted Hazard Ratios for Risk of Congestive Heart Failure Events or Cardiovascular Deaths Among Those Who Initiate Metformin vs Sulfonylurea Among Propensity Score--Matched and Weighted Cohort

                                                                                                 Metformin           Sulfonylurea
  ---------------------------------------------------------------------------------------------- ------------------- -------------------
  Persistent exposure required[a](#jah32175-note-0005){ref-type="fn"}                                                
  N at risk                                                                                      65 986              65 986
  Composite heart failure hospitalization or cardiovascular death                                1078                1236
  Person‐years                                                                                   121 406             99 872
  Unadjusted rate/1000 person‐years                                                              8.9 (8.4, 9.4)      12.4 (11.7, 13.1)
  Adjusted hazard ratio[b](#jah32175-note-0006){ref-type="fn"} (95%CI)                           Reference           1.32 (1.21, 1.43)
  Heart failure hospitalization alone                                                            1043                1184
  Unadjusted rate/1000 person‐years                                                              8.6 (8.1, 9.1)      11.9 (11.2, 12.5)
  Adjusted hazard ratio[b](#jah32175-note-0006){ref-type="fn"} (95%CI)                           Reference           1.30 (1.20, 1.42)
  Cardiovascular death alone                                                                     35                  52
  Unadjusted rate/10 000 person‐years                                                            2.9 (2.1, 4.0)      5.2 (3.9, 6.8)
  Adjusted hazard ratio[b](#jah32175-note-0006){ref-type="fn"} (95%CI)                           Reference           1.76 (1.14, 2.71)
  Composite heart failure emergency department visit, hospitalization, or cardiovascular death   1334                1449
  Person‐years                                                                                   121 147             99 600
  Unadjusted rate/1000 person‐years                                                              11.0 (10.4, 11.6)   15.1 (14.3, 15.8)
  Adjusted hazard ratio[b](#jah32175-note-0006){ref-type="fn"} (95%CI)                           Reference           1.30 (1.20, 1.40)
  Persistent exposure not required[c](#jah32175-note-0008){ref-type="fn"}                                            
  N at risk                                                                                      65 986              65 986
  Composite heart failure hospitalization or cardiovascular death                                4007                4573
  Person‐years                                                                                   323 268             311 040
  Unadjusted rate/1000 person‐years                                                              12.4 (12.0, 12.8)   14.7 (14.3, 15.1)
  Adjusted hazard ratio[b](#jah32175-note-0006){ref-type="fn"} (95%CI)                           Reference           1.21 (1.16, 1.27)
  Weighted analysis of full cohort                                                                                   
  N at risk (weighted)                                                                           126 867             125 362
  Composite heart failure hospitalization or cardiovascular death                                1499                1699
  Person‐years                                                                                   240 948             190 773
  Unadjusted rate/1000 person‐years                                                              6.2 (5.9, 6.5)      8.9 (8.5, 9.3)
  Adjusted hazard ratio[b](#jah32175-note-0006){ref-type="fn"} (95%CI)                           Reference           1.43 (1.32, 1.55)

Primary analysis considers patients persistent on incident regimen until they do not have oral antidiabetic medications for 90 days.

Cox proportional hazards model for time to event. Adjusted for age, sex, race, fiscal year of cohort entry, number of medications, number of outpatient visits, baseline HbA~1c~, body mass index, estimated glomerular filtration rate, low‐density lipoprotein cholesterol, blood pressure, use of medications and health care utilization (see Table [S1](#jah32175-sup-0001){ref-type="supplementary-material"}), smoking‐related illness, cardiovascular disease, serious liver/respiratory disease, cancer, Parkinson disease, mental illness, arrhythmia, cardiac valve disease, asthma/obstructive pulmonary disease, procedures for carotid/peripheral artery revascularization or bypass or lower extremity amputation. All continuous variables were modeled as restricted cubic splines.

Persistent exposure not required analysis in which patients remain in their exposure group, regardless of persistence on drug therapy, until outcome or end of the study.

John Wiley & Sons, Ltd

![Cumulative incidence of heart failure hospitalization or cardiovascular death over time.](JAH3-6-e005379-g002){#jah32175-fig-0002}

We assessed median \[interquartile range\] HbA~1c~ and BMI on the index date and over time for the matched cohort. Baseline HbA~1c~ was 6.9% (51.9 mmol/mol) in both groups, and declined to 6.4% \[6.0, 6.9\] (46.4 mmol/mol \[42.1, 51.9\]) and 6.5% \[6.0, 7.1\] (47.5 mmol/mol \[42.1, 54.1\]) in metformin and sulfonylurea initiators, respectively, by 1.5 years after drug initiation. The HbA~1c~ difference of 0.1% (1.1 mmol/mol) was maintained between groups over follow‐up. Median BMI declined rapidly in metformin initiators, yielding a maximum difference of 0.9 BMI units between groups by 1.5 years. This difference narrowed to 0.5 BMI unit difference at 7.5 years (Figure [3](#jah32175-fig-0003){ref-type="fig"}).

![Median (interquartile range) glycated hemoglobin (HbA~1c~) and body mass index (BMI) of at‐risk patients over time.](JAH3-6-e005379-g003){#jah32175-fig-0003}

Sensitivity and Subgroup Analyses {#jah32175-sec-0016}
---------------------------------

In sensitivity analyses in which patients remained in their original exposure group, (persistent exposure not required), there were 4573 events (4366 heart failure hospitalizations, 207 cardiovascular deaths) among sulfonylurea initiators and 4007 events (3830 heart failure hospitalizations, 177 cardiovascular deaths) among metformin initiators, yielding 14.7 and 12.4 events per 1000 person‐years (aHR 1.21 \[1.16, 1.27\]) (Table [2](#jah32175-tbl-0002){ref-type="table-wrap"}).

In analyses in which sulfonylurea users were weighted to resemble metformin users, there were 1699 and 1499 events among sulfonylurea and metformin users, yielding 8.9 and 6.2 events per 1000 person‐years (aHR 1.43, \[1.32, 1.55\]) (Table [2](#jah32175-tbl-0002){ref-type="table-wrap"}). As a positive control, thiazolidinedione users were compared to weighted metformin users; there were 141 and 154 events, yielding 16.5 (14.0, 19.4) and 10.5 (8.9, 12.2) events per 1000 person‐years (aHR 1.44, \[1.20, 1.74\]).

In the primary analyses, follow‐up began 6 months after the index date to minimize early nonadherence and regimen switching. The alternate weighted analysis of new users evaluating this first 6‐month period found sulfonylurea (N=163 995) versus metformin (N=166 397) had 11.7 (11.0, 12.5) versus 7.8 (7.2, 8.4) events per 1000 person‐years (aHR 1.50 \[1.35, 1.66\]). Those who initiated thiazolidinedione (N=10 164) versus metformin (N=10 200) had 25.7 (21.6, 30.6) versus 14.9 (11.9, 18.7) events per 1000 person‐years (aHR 1.72 \[1.36, 2.18\]) (Table [S5](#jah32175-sup-0001){ref-type="supplementary-material"}). Subgroup analyses demonstrated consistent results including patients both with and without a prior history of heart failure. There was no evidence of effect modification (Figure [4](#jah32175-fig-0004){ref-type="fig"}).

![Adjusted hazard ratio and 95%CIs of subgroups. Two medication adherence requirements tested: persistence to medication required with 90‐day gaps or persistence not required. Sul indicates sulfonylurea; Met, metformin.](JAH3-6-e005379-g004){#jah32175-fig-0004}

Our finding of increased hazard for the composite outcome among sulfonylurea users could in theory have resulted from an unmeasured covariate that is associated with heart failure and was more prevalent among sulfonylurea than metformin users. For example, we observed heart failure history to have a HR of 2.3 for our outcome. An unmeasured confounder of this strength would need to be at least 17% more prevalent among sulfonylurea users. For comparison in the unmatched cohort, baseline heart failure history was only 5% more prevalent. Thus, if an unmeasured confounder comparable to heart failure history existed, it would not change this paper\'s main conclusions (Table [S6](#jah32175-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah32175-sec-0017}
==========

Type 2 diabetes mellitus is linked to obesity and is an independent risk factor for cardiomyopathy.[33](#jah32175-bib-0033){ref-type="ref"}, [34](#jah32175-bib-0034){ref-type="ref"} Patients with type 2 diabetes mellitus have abnormalities in carbohydrate metabolism (insulin resistance) and elevated insulin levels (hyperinsulinemia), which contribute to the development of heart failure.[4](#jah32175-bib-0004){ref-type="ref"}, [35](#jah32175-bib-0035){ref-type="ref"}, [36](#jah32175-bib-0036){ref-type="ref"}, [37](#jah32175-bib-0037){ref-type="ref"} Medications that improve insulin sensitivity and limit weight gain, such as metformin, may be more beneficial than medications that increase endogenous insulin and result in weight gain, such as sulfonylureas. Many hypoglycemics have not been rigorously evaluated for the risk of heart failure.[12](#jah32175-bib-0012){ref-type="ref"}, [38](#jah32175-bib-0038){ref-type="ref"} Clinical trials of diabetes mellitus medications, including the United Kingdom Prospective Diabetes Study, excluded patients with heart failure. The associations reported between heart failure and thiazolidinediones or saxagliptin have been the subject of much debate, in part because these associations were identified as adverse event reports, not as prespecified outcomes in clinical trials that had other surrogate or cardiovascular events as outcomes.[7](#jah32175-bib-0007){ref-type="ref"}, [8](#jah32175-bib-0008){ref-type="ref"}, [39](#jah32175-bib-0039){ref-type="ref"}

In this national cohort of veterans who initiated either metformin or a sulfonylurea for first‐line diabetes mellitus treatment, we found that sulfonylurea initiation was associated with an increased risk of heart failure hospitalization and cardiovascular death compared with metformin initiation. Our comparison groups were carefully matched on important covariates including BMI and HbA~1c~ at therapy initiation. Interestingly, among patients who remained at risk by 1.5 years after initiation, metformin users had on average almost 1 BMI unit lower weight than patients prescribed a sulfonylurea (≈2.9 kg for an average 5 foot 10 inch male) and a 0.1% lower HbA~1c~. The weight differences largely persisted for the study duration. These weight differences are also consistent with findings from the systematic review and a recent network meta‐ analysis.[12](#jah32175-bib-0012){ref-type="ref"}, [40](#jah32175-bib-0040){ref-type="ref"} Bennett reported a pooled 2.5‐kg relative difference in weight for monotherapy between metformin and a sulfonylurea with a high strength of evidence. The network meta‐analysis by Palmer et al[12](#jah32175-bib-0012){ref-type="ref"} reported a standardized mean difference of 0.19‐kg higher weight for sulfonylurea monotherapy users compared with those taking metformin. Nevertheless, it remains unclear to what extent the degree of glycemic control or changes in weight affected the heart failure risk in our study.

Several lines of evidence suggest that weight changes during diabetes mellitus management are associated with heart failure. A meta‐analysis and metaregression[41](#jah32175-bib-0041){ref-type="ref"} combined information from multiple trials to investigate whether glucose‐lowering drugs (predominantly thiazolidinedione or dipeptidyl peptidase‐4 inhibitors) or management strategies (standard versus intensive control) were associated with heart failure. There were 95 502 patients included from 14 trials. The meta‐analysis demonstrated that, compared with standard glucose control, heart failure risk increased with intensive control (risk ratio 1.14 \[1.01, 1.30\]) and was also associated with weight gain (*P*=0.02 for meta‐regression). Each 1.0 kg increase in weight was associated with a 7.1% (95%CI 1.0‐13.6) relative increase in heart failure risk. Conversely, weight loss was associated with a decreased heart failure risk \[risk ratio 0.80 (0.62, 1.04)\]. Another recent observational cohort followed more than 10 000 patients in a United Kingdom diabetes registry for more than 10 years.[42](#jah32175-bib-0042){ref-type="ref"} The risk of incident heart failure was 2 times higher among obese patients (BMI ≥30 kg/m^2^) in all age tertiles compared with patients whose BMI was between 18.5 and 24.9 kg/m^2^.

Possible explanations for our findings include differential medication effects on BMI, as evident in our cohort and others,[42](#jah32175-bib-0042){ref-type="ref"}, [43](#jah32175-bib-0043){ref-type="ref"} and/or differential effects on insulin levels or insulin resistance.[36](#jah32175-bib-0036){ref-type="ref"}, [37](#jah32175-bib-0037){ref-type="ref"} Our study is not mechanistic and cannot establish a causal relationship or distinguish among these hypotheses. However, the BMI difference observed between metformin and sulfonylurea users is consistent with a differential risk of heart failure. We also verified the expected increased association of heart failure with thiazolidinediones versus metformin. This finding and consistent results using different methodologic approaches lend credence to the increased risk observed with sulfonylureas versus metformin. Our results are consistent with the United Kingdom Prospective Diabetes Study and a large cohort within the Clinical Practice Research Database, which found beneficial effects of metformin on heart failure but no benefit from sulfonylurea.[44](#jah32175-bib-0044){ref-type="ref"}, [45](#jah32175-bib-0045){ref-type="ref"} The study by Tzoulaki in the Clinical Practice Research Database found that sulfonylurea was associated with a higher risk of heart failure than metformin, but confidence intervals were wide in fully adjusted models, most likely due to a smaller number of outcome events than in our current study. We estimated sulfonylurea users to have an average of 4 excess heart failure hospitalizations or cardiovascular deaths per 1000 users annually compared to the metformin users.

Our study does have limitations. First, although we utilized multiple strategies to address confounding by indication and disease severity including exclusions, propensity score matching, and covariate adjustment, residual confounding from unmeasured factors, such as patient frailty, remains possible. Our findings were robust when we assessed sensitivity to unmeasured confounders. A hypothetical unmeasured confounder resembling the baseline heart failure history prevalence in prematching imbalance and with a similar strength of association with the outcome would not explain the statistically significant results from our primary analysis (Table [S6](#jah32175-sup-0001){ref-type="supplementary-material"}). Second, veterans may not receive all their care or medications at veteran facilities,[15](#jah32175-bib-0015){ref-type="ref"}, [16](#jah32175-bib-0016){ref-type="ref"} resulting in missing outcomes or medications, which we partially addressed through supplementation with Medicare/Medicaid information. Third, we did not account for time‐varying nonadherence to other medications, such as diuretics, which may lead to heart failure exacerbations. Our groups were matched on baseline characteristics, including medications and comorbidities associated with heart failure risk, and consistent associations were also observed among patients without a history of heart failure. Fourth, to reduce exposure misclassification, follow‐up started 180 days after initiation, and because we required persistence on drug for our primary analysis, the median follow‐up time was short, ≈1 year. Although this approach excluded the initial exposure period, separate evaluations examined the first 6 months and also allowed for nonpersistence and increased follow‐up to an average of 5 years. Both sensitivity analyses produced consistent results. Finally, our population reflects a typical veteran population, predominantly male; therefore, caution is warranted when extrapolating to other settings and to females.

At age 40, the lifetime risk of developing heart failure is 1 in 5. It remains the primary reason for hospital admission among both VHA and Medicare beneficiaries and a major contributor to the \$37.2 billion in heart failure costs in the United States. We found that using sulfonylurea as an initial therapy for diabetes mellitus was associated with more heart failure outcomes than initiation of metformin. Metformin is already the preferred first‐line medical therapy for diabetes mellitus and now can be used safely in another insulin‐resistant state, mild to moderate kidney disease.[46](#jah32175-bib-0046){ref-type="ref"} Despite the recommendation to use metformin, sulfonylurea remains an initial choice for diabetes mellitus treatment in 20%[47](#jah32175-bib-0047){ref-type="ref"} to 30%[27](#jah32175-bib-0027){ref-type="ref"} of the insured and VHA populations, respectively, because of physician preference, relative ease of initiation and titration, and lack of gastrointestinal side effects. Given the clinically important increase in heart failure and other cardiovascular risk associated with sulfonylureas compared with metformin,[13](#jah32175-bib-0013){ref-type="ref"}, [44](#jah32175-bib-0044){ref-type="ref"} it is urgent to determine whether other drugs should be preferred over sulfonylureas for those intolerant to metformin.
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